title: Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus.
abstract: OBJECTIVE
  To establish the prevalence of inflammatory secretory phospholipase A2 (sPLA2) and cytoplasmic phospholipase A2 (cPLA2) expression in a surgical series of Barrett's adenocarcinoma and associated preneoplastic lesions and to correlate this expression with clinicopathological data and prognosis.
  
  
  METHODS
  sPLA2 and cPLA2 were analysed by means of immunohistochemistry in surgical specimens of 67 and 73 cases of Barrett's adenocarcinomas, respectively. Barrett's mucosa was analysed in 31 cases.
  
  
  RESULTS
  Expression of sPLA2 was detected in 48% of Barrett's mucosa negative for intraepithelial neoplasia and 63% of Barrett's adenocarcinoma. Semi-quantitative analysis revealed a significant increase in sPLA2 expression between Barrett's mucosa negative for intraepithelial neoplasia and adenocarcinoma. cPLA2 expression was detected in 18% of Barrett's adenocarcinoma. An inverse correlation was found between cPLA2 expression and depth of tumour infiltration, neoplastic vascular invasion and neoplastic perineural invasion. Survival analysis showed no significant prognostic value for sPLA2 and cPLA2.
  
  
  CONCLUSIONS
  sPLA2 is frequently expressed in Barrett's oesophagus. The increasing expression of sPLA2 that we observed from Barrett's mucosa to adenocarcinoma suggests that sPLA2 could be involved in Barrett's carcinogenesis. In contrast, cPLA2 expression is less frequently observed in Barrett's oesophagus and is inversely associated with aggressive pathological features of the tumours.
authors.affiliation: Service d'Anatomie Pathologique, Hôpital Avicenne, AP-HP, Bobigny, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Lagorce-Pagès
authors.forename: François
authors.initials: F
authors.lastname: Paraf
authors.forename: Dominique
authors.initials: D
authors.lastname: Wendum
authors.forename: Antoine
authors.initials: A
authors.lastname: Martin
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Fléjou
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology* / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001471:Barrett Esophagus / Q000201:enzymology* / Q000473:pathology; D014408:Biomarkers, Tumor / Q000378:metabolism; D003600:Cytosol / Q000201:enzymology; D004938:Esophageal Neoplasms / Q000201:enzymology* / Q000473:pathology; D005260:Female; D054501:Group II Phospholipases A2; D054513:Group IV Phospholipases A2; D006801:Humans; D007124:Immunoenzyme Techniques; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D011230:Precancerous Conditions / Q000201:enzymology* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D007527:Isoenzymes; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054513:Group IV Phospholipases A2; D054467:Phospholipases A2